The Traderszone Network

Published in TZ Latest News 7 December, 2015 by The TZ Newswire Staff

Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)